Uniphar

Uniphar, a Pharmaceutical Preparation Manufacturing company headquartered in Ireland, reported its Scope 1 and 2 emissions for 2025 as about 5,112,280 kg CO2e. This includes approximately 2,744,570 kg CO2e from Scope 1 emissions, comprising 1,723,880 kg CO2e from mobile combustion, 170,130 kg CO2e from fugitive emissions, and 850,560 kg CO2e from stationary combustion. Scope 2 emissions for 2025 were approximately 2,367,710 kg CO2e, primarily from purchased electricity.

For 2024, Uniphar's Scope 1 emissions were approximately 2,833,110 kg CO2e, and Scope 2 emissions were about 3,190,550 kg CO2e. In 2023, Uniphar's Scope 1 emissions were approximately 2,969,970 kg CO2e, Scope 2 emissions were about 3,358,930 kg CO2e, and Scope 3 emissions were approximately 875,620,000 kg CO2e. Significant Scope 3 categories in 2023 included purchased goods and services (about 780,504,000 kg CO2e) and upstream transportation and distribution (approximately 73,939,000 kg CO2e).

Uniphar has set near-term science-based targets. The company commits to reducing absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030, using 2019 as the base year. Additionally, Uniphar aims for 73.5% of its suppliers, by emissions covering purchased goods and services, to have science-based targets by 2027. These targets are consistent with reductions required to keep global warming to 1.5°C, as validated by the Science Based Targets initiative (SBTi).